OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
GIPL.PK55

Global Innovative Platforms Inc

Advanced Medical Equipment & TechnologyVerified

The company's capital structure is highly leveraged, with total liabilities of $201,000 million and total equity of -$200,400 million, resulting in a debt-to-equity ratio of -0.94. The company has no liquidity buffer, as its current ratio is 0.0, and its cash and equivalents of $600 million are entirely offset by long-term debt of $187,860 million. The negative net cash position raises concerns about its ability to meet short-term obligations without external financing. Profitability metrics are severely negative, with a net loss of $3,890 million and an operating loss of the same amount. Return on equity is 1.94%, which is likely below the industry median for Advanced Medical Equipment & Technology, given the company's negative equity base. Return on assets is -6.48%, indicating that the company is destroying value on its asset base. These metrics suggest a high-risk profile with no clear path to profitability. The company does not disclose segment or geographic revenue breakdowns in the available data, so it is not possible to assess revenue concentration or geographic exposure. However, the absence of such disclosures may indicate a lack of diversification or transparency in its business model. The company's growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance. The absence of revenue in the latest financial snapshot and the consistent net loss suggest a lack of commercial traction or operational scalability. Without a demonstrated ability to generate revenue, the company's long-term viability is questionable. The company faces significant liquidity and dilution risks. Its negative equity and high debt load suggest a potential need for equity financing, which could dilute existing shareholders. The risk assessment indicates a low probability of dilution in the near term, but the company's financial position makes it vulnerable to capital calls or restructuring. The negative operating cash flow of $27,230 million further exacerbates liquidity concerns. No recent events, such as filings or transcripts, are available in the provided data to inform the company's current strategic direction or operational developments. The lack of recent disclosures may indicate limited public activity or a focus on private operations.

30-day price · GIPL.PK(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyGlobal Innovative Platforms Inc
TickerGIPL.PK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Global Innovative Platforms Inc develops and commercializes advanced medical equipment and technology solutions, primarily serving the healthcare services and equipment sector.

Classification. The company is classified under the Healthcare economic sector, Healthcare Services & Equipment business sector, and Advanced Medical Equipment & Technology industry with a confidence level of 0.92.

The company's capital structure is highly leveraged, with total liabilities of $201,000 million and total equity of -$200,400 million, resulting in a debt-to-equity ratio of -0.94. The company has no liquidity buffer, as its current ratio is 0.0, and its cash and equivalents of $600 million are entirely offset by long-term debt of $187,860 million. The negative net cash position raises concerns about its ability to meet short-term obligations without external financing. Profitability metrics are severely negative, with a net loss of $3,890 million and an operating loss of the same amount. Return on equity is 1.94%, which is likely below the industry median for Advanced Medical Equipment & Technology, given the company's negative equity base. Return on assets is -6.48%, indicating that the company is destroying value on its asset base. These metrics suggest a high-risk profile with no clear path to profitability. The company does not disclose segment or geographic revenue breakdowns in the available data, so it is not possible to assess revenue concentration or geographic exposure. However, the absence of such disclosures may indicate a lack of diversification or transparency in its business model. The company's growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance. The absence of revenue in the latest financial snapshot and the consistent net loss suggest a lack of commercial traction or operational scalability. Without a demonstrated ability to generate revenue, the company's long-term viability is questionable. The company faces significant liquidity and dilution risks. Its negative equity and high debt load suggest a potential need for equity financing, which could dilute existing shareholders. The risk assessment indicates a low probability of dilution in the near term, but the company's financial position makes it vulnerable to capital calls or restructuring. The negative operating cash flow of $27,230 million further exacerbates liquidity concerns. No recent events, such as filings or transcripts, are available in the provided data to inform the company's current strategic direction or operational developments. The lack of recent disclosures may indicate limited public activity or a focus on private operations.
Key takeaways
  • The company has a highly leveraged capital structure with a negative equity position and no liquidity buffer.
  • Profitability is severely negative, with a net loss of $3,890 million and a return on assets of -6.48%.
  • The company lacks segment and geographic revenue disclosures, making it difficult to assess diversification.
  • Growth is uncertain due to the absence of revenue and consistent net losses.
  • Liquidity and dilution risks are elevated, with a negative operating cash flow and high debt load.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$0.00
Gross profit
Operating income-$3.9k
Net income-$3.9k
R&D
SG&A
D&A
SBC
Operating cash flow-$27.2k
CapEx
Free cash flow
Total assets$600.00
Total liabilities$201.0k
Total equity-$200.4k
Cash & equivalents$600.00
Long-term debt$187.9k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$0.00-$73.3k-$73.3k
FY-3$0.00-$53.8k-$53.8k-$53.8k
FY-2$0.00-$282.8k-$282.8k-$282.8k
FY-1$0.00-$136.2k-$136.2k
FY0$0.00-$718.2k-$718.2k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$260.00-$28.9k$260.00
FY-3$47.8k-$82.7k$47.8k
FY-2$420.00-$363.9k$420.00
FY-1$20.00-$33.1k$20.00
FY0$199.3k$187.7k$17.8k
PeriodOCFCapExFCFSBC
FY-4$260.00
FY-3-$53.6k-$53.8k
FY-2-$234.8k-$282.8k
FY-1-$87.4k
FY0-$560.7k-$175.4k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$0.00-$3.9k-$3.9k
FQ-6$0.00-$6.4k-$6.4k
FQ-5$0.00-$76.5k-$76.5k
FQ-4-$120.5k-$120.5k
FQ-3$0.00-$151.3k-$151.3k
FQ-2$0.00-$211.8k-$211.8k
FQ-1$0.00-$234.6k-$234.6k
FQ0$30.0k-$49.4k-$49.4k-$44.4k
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$600.00-$200.4k$600.00
FQ-6$10.2k-$206.8k$10.2k
FQ-5$20.00-$33.1k$20.00
FQ-4$148.5k$134.1k$148.5k
FQ-3$166.9k$163.7k$155.9k
FQ-2$209.2k$181.3k$198.1k
FQ-1$199.3k$187.7k$17.8k
FQ0$224.9k$159.2k$49.0k
PeriodOCFCapExFCFSBC
FQ-7-$27.2k
FQ-6-$27.7k
FQ-5-$87.4k
FQ-4-$138.1k
FQ-3-$311.6k
FQ-2-$495.9k
FQ-1-$560.7k-$175.4k
FQ0$12.7k-$44.4k
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$200.4k
Net cash-$187.3k
Current ratio0.0
Debt/Equity-0.9
ROA-6.5%
ROE1.9%
Cash conversion7.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 109 companies
MetricGIPL.PKActivity
Op margin-19.9% medp25 -150.5% · p75 8.7%
Net margin-18.4% medp25 -146.8% · p75 8.0%
Gross margin49.9% medp25 36.2% · p75 66.3%
R&D / revenue6.2% medp25 4.7% · p75 12.0%
CapEx / revenue-3.5% medp25 -7.8% · p75 -1.4%
Debt / equity-94.0%14.5% medp25 0.9% · p75 54.2%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 01:09 UTC#f3d5ffc2
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 00:54 UTCJob: 63d8b5d7